Background Triple-negative breast cancer (TNBC) is associated with aggressiveness and a
poor prognosis. Besides surgery, radiotherapy serves as the major treatment modality for …

Purpose Triple-negative breast cancer (TNBC) is the most aggressive form of breast cancer,
accounting for 20% of cases. Due to the lack of a molecular target, limited options are …

Radiation is widely used for cancer treatment but the radioresistance properties of cancer
stem cells (CSCs) pose a significant challenge to the success of cancer therapy. Nuclear …

Radiotherapy, a frequent mode of cancer treatment, is often restricted by dose-related
toxicity and development of therapeutic resistance. To develop a novel and selective …

Introduction Expression of Y-box binding protein-1 (YB-1) is associated with tumor
progression and drug resistance. Phosphorylation of YB-1 at serine residue 102 (S102) in …

Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype.
Radiotherapy is an effective option for the treatment of TNBC; however, acquired …

Purpose: The epidermal growth factor receptor (EGFR) plays an important role in cellular
response to chemotherapy and radiotherapy through modulation of DNA repair. EGFR …

Purpose Y-box binding protein 1 (YB-1) overexpression is associated with chemotherapy-
and radiation therapy resistance. Ionizing radiation (IR), receptor tyrosine kinase ligands …

Women with triple-negative breast cancer (TNBC) are generally treated by chemotherapy
but their responsiveness may be blunted by DNA double-strand break (DSB) repair. We …

The human actin-binding protein filamin-A (also known as ABP-280) cross-links actin into a
dynamic three-dimensional structure. It interacts with> 45 proteins of diverse functions …